BioCentury
ARTICLE | Clinical News

Selincro nalmefene regulatory update

October 13, 2014 7:00 AM UTC

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Selincro nalmefene to help reduce alcohol consumption in adults with alcohol dependence who have a high drinking risk level without physical withdrawal symptoms and who do not require immediate detoxification -- its approved indication in the EU. The label states that Selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. The FAD is in line with a preliminary appraisal issued in July. Final guidance is expected next month. ...